Overview
Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19
Status:
Recruiting
Recruiting
Trial end date:
2020-10-31
2020-10-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
Ivermectin which is an FDA-approved broad spectrum anti-parasitic agent, has also anti-viral activity. In vitro study have shown its activity against SARS-CoV-2, however its clinical effect on patients with COVID-19 never been tested. In this RCT we would like to evaluate the effect of Ivermectin on reduction of viral shedding among mild to moderate COVID-19 patients, and in shortening the symptom resolution time.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Sheba Medical CenterTreatments:
Ivermectin
Criteria
Inclusion Criteria:Participants eligible for inclusion will include non-pregnant adult (>18 years old) with
molecular confirmation of COVID-19. [Participants will be eligible in a period of no longer
than 72 hours after exposure].
Exclusion Criteria:
- Severe infection ( defined as need for invasive or non-invasive ventilator support,
ECMO or shock requiring vasopressor support).
- Weight below 40Kg or above 100Kg
- Unable to take oral medication
- Known allergy to the drugs
- Pregnancy or breast feeding
- Participating in another RCT for treatment of COVID-19.